Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial-Reference-Cited by-同舟云学术

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Published:2019-04-12 Issue:6 Volume:285 Page:653-669
ISSN:0954-6820
Container-title:Journal of Internal Medicine
language:en
Short-container-title:J Intern Med

Author:

Goll G. L.¹,Jørgensen K. K.²,Sexton J.¹,Olsen I. C.¹³,Bolstad N.⁴,Haavardsholm E. A.¹⁵,Lundin K. E. A.⁵⁶⁷,Tveit K. S.⁸,Lorentzen M.⁹,Berset I. P.¹⁰,Fevang B. T. S.¹¹,Kalstad S.¹²,Ryggen K.¹³,Warren D. J.⁴,Klaasen R. A.⁴,Asak Ø.¹⁴,Baigh S.¹⁵,Blomgren I. M.¹⁶,Brenna Ø.¹⁷,Bruun T. J.¹²,Dvergsnes K.¹⁸,Frigstad S. O.¹⁹,Hansen I. M.²⁰,Hatten I. S. H.²¹,Huppertz‐Hauss G.²²,Henriksen M.²³,Hoie S. S.²⁴,Krogh J.²⁵,Midtgard I. P.²⁶,Mielnik P.²⁷,Moum B.⁵²⁸,Noraberg G.²⁹,Poyan A.³⁰,Prestegård U.³¹,Rashid H. U.³²,Strand E. K.³³,Skjetne K.¹³,Seeberg K. A.³⁴,Torp R.³⁵,Ystrøm C. M.³⁶,Vold C.³⁷,Zettel C. C.³⁸,Waksvik K.³⁹,Gulbrandsen B.⁴⁰,Hagfors J.⁴¹,Mørk C.⁴²,Jahnsen J.²⁵,Kvien T. K.¹⁵

Affiliation:

1. Department of Rheumatology Diakonhjemmet Hospital OsloNorway

2. Department of Gastroenterology Akershus University Hospital LørenskogNorway

3. Research Support Services CTU Oslo University Hospital Oslo Norway

4. Department of Medical Biochemistry Oslo University Hospital RadiumhospitaletOsloNorway

5. Institute of Clinical Medicine University of OsloOsloNorway

6. Department of Gastroenterology Oslo University Hospital RikshospitaletOsloNorway

7. K.G. Jebsen Coeliac Disease Research Centre University of Oslo OsloNorway

8. Department of Dermatology Haukeland University Hospital BergenNorway

9. Department of Dermatology Oslo University Hospital Rikshospitalet OsloNorway

10. Department of Gastroenterology Ålesund Hospital ÅlesundNorway

11. Department of Rheumatology Haukeland University Hospital BergenNorway

12. Department of Rheumatology University Hospital of Northern Norway TromsøNorway

13. Department of Dermatology Sankt Olav's Hospital TrondheimNorway

14. Department of Gastroenterology Gjøvik Hospital GjøvikNorway

15. Department of Dermatology Haugesund Hospital HaugesundNorway

16. Department of Gastroenterology Haugesund Hospital HaugesundNorway

17. Department of Gastroenterology Sankt Olav's Hospital TrondheimNorway

18. Department of Gastroenterology Sørlandet Hospital KristiansandNorway

19. Department of Gastroenterology Bærum Hospital BærumNorway

20. Department of Rheumatology Helgelandssykehuset Mo I RanaNorway

21. Department of Dermatology Førde Hospital FørdeNorway

22. Department of Gastroenterology Telemark Hospital SkienNorway

23. Department of Gastroenterology Østfold Hospital FredrikstadNorway

24. Department of Rheumatology Sørlandet Hospital KristiansandNorway

25. Department of Rheumatology Levanger Hospital LevangerNorway

26. Department of Rheumatology Bodø Hospital BodøNorway

27. Department of Rheumatology Førde Hospital FørdeNorway

28. Department of Gastroenterology Oslo University Hospital Ullevål OsloNorway

29. Department of Gastroenterology Sørlandet Hospital ArendalNorway

30. Department of Rheumatology Kongsvinger Hospital KongsvingerNorway

31. Department of Gastroenterology Lillehammer Hospital LillehammerNorway

32. Department of Rheumatology Østfold Hospital MossNorway

33. Department of Rheumatology Revmatismesykehuset LillehammerNorway

34. Department of Gastroenterology Vestfold Hospital TønsbergNorway

35. Department of Gastroenterology Hamar Hospital HamarNorway

36. Department of Gastroenterology Elverum Hospital ElverumNorway

37. Department of Gastroenterology Bodø Hospital BodøNorway

38. Department of Rheumatology Betanien Hospital SkienNorway

39. Patient representative Norges Psoriasis‐ og eksemforbundTrondheimNorway

40. Patient representative Landsforeningen for fordøyelsessykdommerOsloNorway

41. Patient representative Norsk RevmatikerforbundOsloNorway

42. Institute of Cancer Research and Molecular Medicine Faculty of Medicine Norwegian University of Science and Technology Trondheim Norway

Funder

Helse- og Omsorgsdepartementet

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.12880

Reference22 articles.

1. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

2. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?

3. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons

4. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

5. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biosimilars in IBD: What Every Clinician Needs to Know;Current Gastroenterology Reports;2024-01-20

2. Biosimilar tocilizumab—better access and lower cost?;The Lancet Rheumatology;2024-01

3. Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway;Expert Opinion on Biological Therapy;2023-11

4. Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis;PLOS ONE;2023-10-03

5. Documento de consenso sobre los medicamentos biosimilares en enfermedades inmunomediadas en España;Reumatología Clínica;2023-10